Baby Rabbit Complement
Baby rabbit complement serum preparation is intended for use as a source of rabbit complement for cytotoxicity studies.
- Product Form
- Pack Size: 1 mlBaby rabbit serum - lyophilizedPack Size: 2 mlBaby rabbit serum - lyophilised
- Pack Size: 1 mlReconstitute with 1.0 ml ice cold distilled waterPack Size: 2 mlReconstitute with 2ml ice cold distilled water
- Preservative Stabilisers
- None present
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC for 1 hour or aliquot and store at -70oC for longer.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the product. Should this product contain a precipitate we recommend microcentrifugation before use.
- Guaranteed until date of expiry. Please see product label.
- For research purposes only
Applications of Baby Rabbit Complement
|Application Name||Verified||Min Dilution||Max Dilution|
|Functional Assays 1|
- 1 This product is not sold as sterile but can be sterilized by filtration if necessary. It is preferable to dilute the complement to a final working concentration before filtration in order to minimize loss of volume.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Instructions For Use
- Use within one hour of reconstitution, keeping on ice throughout.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Product Specific References
References for Baby Rabbit Complement
Council of Europe. (1983) Essential aspects of tissue typing: Preparation, use, storage of reagents and standardisation of complement.
European Health Committee, Strasbourg, ISBN 92-871.224-4.
Edited by J.G.Ray. (1979) NIAID Manual of tissue typing techniques.
Publication No. NIH-80-545.
Anderson, L.D. Jr et al. (1999) Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
Cancer Res. 59 (7): 1525-30.
Mason, J.C. et al. (2002) Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
Circ Res. 91 (8): 696-703.
Lidington, E.A. et al. (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.
Blood. 96 (8): 2784-92.
De clercq, L. et al. (1997) An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes in vitro and depresses the development of pig adipose tissue.
J Anim Sci. 75 (7): 1791-7.
Hung, M.C. et al. (2011) The Neisseria meningitidis Macrophage Infectivity Potentiator Protein Induces Cross-Strain Serum Bactericidal Activity and Is a Potential Serogroup B Vaccine Candidate.
Infect Immun. 79: 3784-91.
Lee, S.J. et al. (2012) Identification of a common immune signature in murine and human systemic Salmonellosis.
Proc Natl Acad Sci U S A. 109 (13): 4998-5003.
Goh, Y.S. & MacLennan, C.A. (2013) Invasive African nontyphoidal Salmonella requires high levels of complement for cell-free antibody-dependent killing.
J Immunol Methods. 387 (1-2): 121-9.
Li, S.H. et al. (2004) C-reactive protein upregulates complement-inhibitory factors in endothelial cells.
Circulation. 109: 833-6.
Hyams, C. et al. (2010) Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype.
Infect Immun. 78: 716-25.
Newcombe, J. et al. (2004) Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.
Infect Immun. 72: 338-44.
Mason, J.C. et al. (2002) bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction.
Am J Physiol Cell Physiol. 282: C578-87.
Sancho, D. et al. (2006) CD69 targeting differentially affects the course of collagen-induced arthritis.
J Leukoc Biol. 80: 1233-41.
Hung MC et al. (2013) The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential.
MBio. 4 (2): pii: e00041-13.
Goh YS et al. (2016) Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection.
PLoS Negl Trop Dis. 10 (4): e0004604.
Sawant S et al. (2016) Establishment of 3D Co-Culture Models from Different Stages of Human Tongue Tumorigenesis: Utility in Understanding Neoplastic Progression.
PLoS One. 11 (8): e0160615.
Humbert MV et al. (2016) Vaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of Neisseria meningitidis.
PLoS One. 11 (8): e0160403.
Nganje, C.N. et al. (2019) PepN is a non-essential, cell wall-localized protein that contributes to neutrophil elastase-mediated killing of Streptococcus pneumoniae.
PLoS One. 14 (2): e0211632.